MNG881
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG911 | — | — | 0.859 |
| 2 | SJEPD031385_D1.RNA-Seq | EPN | EPN Tumor | 0.836 |
| 3 | MNG876 | — | — | 0.824 |
| 4 | SRR25617900 | — | A | 0.816 |
| 5 | MNG884 | — | — | 0.809 |
| 6 | MNG516 | — | — | 0.804 |
| 7 | MNG938 | — | — | 0.803 |
| 8 | MNG59 | — | — | 0.799 |
| 9 | MNG200 | — | — | 0.798 |
| 10 | MNG73 | — | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.356 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.268 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.178 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.125 | Remibrutinib | — uncovered |
| PEROXISOME | 0.112 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.109 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.103 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.078 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.076 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.044 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.005 | Inavolisib | — uncovered |